A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials

(2014) Sufia Butt Hassan et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Agonistic CD40 Antibodies and Cancer Therapy

(2013) R. H. Vonderheide et al.   CLINICAL CANCER RESEARCH

Pilot study of dacetuzumab in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma

(2012) Andres Forero-Torres et al.   LEUKEMIA & LYMPHOMA

A phase I multidose study of dacetuzumab (SGN-40; humanized anti-CD40 monoclonal antibody) in patients with multiple myeloma

(2010) M. Hussein et al.   HAEMATOLOGICA

Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma

(2009) Ranjana Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma

(2009) Wen-Kai Weng et al.   LEUKEMIA & LYMPHOMA

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

(2008) Robert Marcus et al.   JOURNAL OF CLINICAL ONCOLOGY

Constitutive CD40 signaling in B cells selectively activates the noncanonical NF-κB pathway and promotes lymphomagenesis

(2008) Cornelia Hömig-Hölzel et al.   JOURNAL OF EXPERIMENTAL MEDICINE